Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clevudine,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Leukavir, an Antiviral Agent for Bukwang Pharm, Confirmed the Effect on New Coronavirus
Details : Levovir (clevudine) was found to be effective on virus isolated from the specimens of Korean Coronavirus Infectious Disease-19 (COVID-19) patients, similar to calletra used for the treatment of COVID-19 in vitro.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2020
Lead Product(s) : Clevudine,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolimidone,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : Melior Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2017
Lead Product(s) : Tolimidone,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : Melior Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolimidone,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : Melior Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Adult Subjects With Uncontrolled Type 2 Diabetes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2014
Lead Product(s) : Tolimidone,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : Melior Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivoceranib,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Elevar Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose-Escalation and Safety Trial of YN968D1
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2011
Lead Product(s) : Rivoceranib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Elevar Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
